Personalised to support your treatment decisions
Inovio has announced positive interim clinical data of INO 4800 vaccine candidate against novel coronavirus (SARS-CoV-2), from the first two Phase I clinical trial cohorts. In addition, INO 4800 has been selected to participate in a non-human primate (NHP) challenge study as part of the U.S. government's Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective vaccine by January 2021.
Ardelyx announced the submission of a New Drug Application (NDA) for Ibsrela (tenapanor) to the FDA for the control of serum phosphorus (hyperphosphatemia) in adult patients with chronic kidney disease (CKD) on dialysis.
Kiniksa Pharmaceuticals announced that the Phase III RHAPSODY trial showed that rilonacept achieved its primary and all major secondary efficacy endpoints in patients with recurrent pericarditis. Results show that prespecified primary and all major secondary efficacy endpoints were highly statistically significant.
You may be interested in...
6th International Conference: Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment
The successful biannual ESH Conferences on acute myeloid leukemia (AML) have established themselves as scientific and educational programs at the interphase of molecular and biologic developments and clinical translation.
The Haematological Tumour Microenvironment and its Therapeutic Targeting 2021
This workshop brings together a constantly growing and international community of researchers, physicians and physician scientists, as well as biologists and physicians in training and corporate representatives, whose present or future work is focused on the tumor microenvironment in the haematological malignancies.